Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Vertex Pharmaceuticals and the drug discovery arm of the Cystic Fibrosis Foundation have expanded their research alliance. Vertex will get another $75 million up front and up to $6 million annually under the new pact. The partners have collaborated since 1998, with CFF contributing upward of $100 million to the company’s R&D prior to the approval of Kalydeco, the first disease-modifying cystic fibrosis treatment. In 2014, CFF sold its royalty rights to all of Vertex’s approved cystic fibrosis drugs for $3.3 billion.
This article has been sent to the following recipient: